» Articles » PMID: 8189453

Inappropriate Breast Secretions of Possible Bacterial Etiology in the Parous Nonpuerperal Female

Overview
Publisher Elsevier
Specialty General Medicine
Date 1994 Mar 1
PMID 8189453
Authors
Affiliations
Soon will be listed here.
Abstract

This article presents two cases of spontaneous green breast secretions of parous nonpuerperal patients. To understand the nature of these secretions, bacterial evaluations and subsequent treatment were undertaken. Case 1 culture and sensitivity studies from breast secretions were commenced within 24 hours yielding an isolate identified as Staphylococcus epidermidis, with sensitivity to cephalothin, erythromycin, and tetracycline but resistant to penicillin. Cephalothin, 500 mg four times a day for 10 days, followed by erythromycin 100 mg twice a day for 10 days and doxycycline 100 mg twice a day for 10 days, did not alter the breast secretions. Four weeks later, ciprofloxacin HCI 500 mg twice a day for 6 weeks caused a 50% decrement in breast secretion at 4 weeks but increased clinical depression. At 6 weeks, no evidence of breast secretions persisted. Mental depression decreased within 2 weeks postciprofloxacin treatment. In Case 2, a total of 35 minutes elapsed between sample collection and initiation of culture and sensitivity studies. Moraxella osloensis was identified and found sensitive to ampicillin and tetracycline but resistant to trimethoprim. Ampicillin 500 mg four times a day for 10 days and doxycycline 100 mg twice a day by mouth for 10 days were administered at 2-week intervals with no effect on breast discharge. After 4 weeks of treatment failure, ciprofloxacin HCI 500 mg twice a day for 6 weeks caused a 50% decrease in discharge at 2 weeks and total elimination at 6 weeks. Lethargy during treatment ceased with termination of therapy. These results support the importance of bacterial evaluation of breast secretions with subsequent antibiotic therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

References
1.
Falser N, Dalhoff A, Weuta H . Ciprofloxacin concentrations in tonsils following a single intravenous infusion. Infection. 1984; 12(5):355-7. DOI: 10.1007/BF01651152. View

2.
Shrire L, Saunders J, Traynor R, Koornhof H . A laboratory assessment of ciprofloxacin and comparable antimicrobial agents. Eur J Clin Microbiol. 1984; 3(4):328-32. DOI: 10.1007/BF01977488. View

3.
Wolfson J, Hooper D . The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985; 28(4):581-6. PMC: 180310. DOI: 10.1128/AAC.28.4.581. View

4.
Hooper D, Wolfson J . The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985; 28(5):716-21. PMC: 176369. DOI: 10.1128/AAC.28.5.716. View

5.
Marble D, Bosso J . Norfloxacin: a quinoline antibiotic. Drug Intell Clin Pharm. 1986; 20(4):261-6. DOI: 10.1177/106002808602000402. View